Diabetes med cardio boost

A multinational study involving Australian researchers has found more evidence for cardiovascular benefits associated with the newest group of oral medications used to treat type 2 diabetes New research has provided further support for cardiovascular benefits associated with sodium-glucose co-transporter-2 (SGLT2) inhibitors, which are glucose-lowering drugs widely used in the treatment of type 2 diabetes.